EUCTR2017-003284-35-ES进行中（未招募）1 期
A follow-up Phase IIa study to evaluate the long-term safety and efficacy profile of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis - A follow-up study in patients with moderate to severe active ulcerative colitis.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ABIVAX
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject will be eligible for inclusion in this study only if ALL of the following criteria apply:
- •Subjects previously enrolled in the ABX464-101 clinical study who have completed the initial 2-month treatment phase;
- •Subjects able and willing to comply with study visits and procedures;
- •Subjects with hematological and biochemical laboratory parameters as follows at the D56 visit of the ABX464-101 study:
- •oHemoglobin > 9.0 g dL-1;
- •oAbsolute neutrophil count = 750 mm-3;
- •oPlatelets = 100,000 mm-3;
- •oTotal serum creatinine = 1.3 x ULN (upper limit of normal);
- •oCreatinine clearance > 50 mL min-1 by the
- •Cockcroft-Gault equation within 60 days of entry;
- •oTotal serum bilirubin < 1.5 x ULN;
- •oAlkaline phosphatase, AST (SGOT) and ALT (SGPT) < 1.5 x
- •-Subjects should understand, sign and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures being performed;
- •-Subjects should be affiliated to a social security regimen (for French sites only);
- •-Females and males receiving the study treatment and their partners must agree to use a highly effective contraceptive method during the study and for 3 months after end of study or early termination. Contraception should be in place at least 2 weeks prior to study participation. Women must be surgically sterile or if of childbearing potential must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception associated with inhibition of ovulation, intrauterine hormone releasing system (IUS), hormonal contraception (estrogen and progestogen or progestogen only) associated with inhibition of ovulation, bilateral tubal occlusion, vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •Any condition, which in the opinion of the investigator, could compromise the subject's safety or the adherence to the study protocol.
研究者
相似试验
进行中（未招募）
1 期
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-003284-35-PLABIVAX30
进行中（未招募）
1 期
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-003284-35-HUABIVAX30
进行中（未招募）
1 期
A follow-up study in patients with moderate to severe active ulcerative colitis.EUCTR2017-003284-35-BEABIVAX30
已完成
2 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Christmas disease1006447710005330NL-OMON54158CSL Behring LLC6
进行中（未招募）
1 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Haemophilia BMedDRA version: 20.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2020-000739-28-DKuniQure biopharma B.V.10